Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 5,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Cancer Clear all
Terminated Phase 1 Interventional

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

NCT02635061
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
ACY-241, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 28, 2026, 8:37 PM EDT
Completed No phase listed Observational

S9925: Collecting and Storing Samples From Patients With Lung Cancer

NCT00920010
View directory record Official record
Conditions
Lung Cancer
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
431
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 283 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 28, 2026, 8:37 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

NCT04803227
View directory record Official record
Conditions
Covid19
Interventions
Emricasan, Placebo
Drug · Other
Lead sponsor
Histogen
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 28, 2026, 8:37 PM EDT
Active, not recruiting Phase 1 Interventional

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

NCT03824327
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

NCT01900652
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Emibetuzumab, Erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02366143
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
61
States / cities
Chandler, Arizona • Flagstaff, Arizona • Bellflower, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 28, 2026, 8:37 PM EDT
Terminated Phase 2 Interventional Results available

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.

NCT01752023
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02001623
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Orange, California • New Haven, Connecticut • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

NCT01761240
View directory record Official record
Conditions
Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions
MORAb-066
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 28, 2026, 8:37 PM EDT
Recruiting Phase 4 Interventional

Erector Spinae Block for Thoracic Surgery

NCT05521789
View directory record Official record
Conditions
Pulmonary Neoplasm, Pulmonary Cancer, Thoracic Diseases, Thoracic Cancer, Thoracic Neoplasms
Interventions
ESB Thoracic
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 28, 2026, 8:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MK-3475, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 28, 2026, 8:37 PM EDT
Terminated Phase 1 Interventional Results available

Hepatic Impairment Study for Lorlatinib in Cancer Patients

NCT03726333
View directory record Official record
Conditions
Advanced Cancers
Interventions
lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

NCT05119855
View directory record Official record
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions
9vHPV Vaccine, mRNA-1273 Vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 11 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 28, 2026, 8:37 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Lung Chemoemobolization

NCT05672108
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm, Lung Metastases From Any Primary, Endobronchial Metastases, Colon Cancer, Sarcoma
Interventions
Computed Tomography, Ethiodized Oil, Mitomycin, Transarterial Chemoembolization, Tris-acryl Gelatin Microspheres
Procedure · Drug · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Not applicable Interventional Results available

Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies

NCT02702921
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Surgeon's 'standard of care' stapler, Ethicon Powered Vascular Stapler
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 28, 2026, 8:37 PM EDT
Terminated No phase listed Observational

A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

NCT02705404
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma Non-small-cell Lung
Interventions
Multifocal Tissue Banking
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

NCT02250885
View directory record Official record
Conditions
Carcinoma, Neuroendocrine
Interventions
Selinexor
Drug
Lead sponsor
Gabrail Cancer Center Research
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

NCT00768755
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
axitinib, chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Atlanta, Georgia • Decatur, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 28, 2026, 8:37 PM EDT
Active, not recruiting Not applicable Interventional Results available

Lymphocyte Depletion and Change in Lymphocyte Functionality

NCT04273893
View directory record Official record
Conditions
Lymphocyte Depletion
Interventions
SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
Radiation · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers

NCT00691132
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder
Interventions
phenethyl isothiocyanate, placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 28, 2026, 8:37 PM EDT
Terminated Not applicable Interventional

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

NCT02673021
View directory record Official record
Conditions
Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Metastatic Cancer to the Lung
Interventions
Microwave ablation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 28, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community Support Program for Lung Cancer Screening

NCT06207435
View directory record Official record
Conditions
Lung Cancer, Behavior
Interventions
Transportation
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 28, 2026, 8:37 PM EDT